GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Total Current Liabilities

F-star Therapeutics (F-star Therapeutics) Total Current Liabilities : $14.68 Mil (As of Sep. 2022)


View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. F-star Therapeutics's total current liabilities for the quarter that ended in Sep. 2022 was $14.68

F-star Therapeutics Total Current Liabilities Historical Data

The historical data trend for F-star Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics Total Current Liabilities Chart

F-star Therapeutics Annual Data
Trend Dec19 Dec20 Dec21
Total Current Liabilities
29.89 16.98 12.14

F-star Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.84 12.14 12.65 15.32 14.68

F-star Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

F-star Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.05+0.906
+Other Current Liabilities+Current Deferred Liabilities
=4.179+0
=12.14

F-star Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2022 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=7.72+2.141
+Other Current Liabilities+Current Deferred Liabilities
=4.814+0
=14.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

F-star Therapeutics Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Total Current Liabilities
Comparable Companies
BDTX DBTX CMRA CGTX MEIP HEPA MTEM ETNB NHWK UBX OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX HKSE:02269 SGEN SZSE:300122
Traded in Other Exchanges
N/A
Address
Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT
Website
https://www.f-star.com
F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.
Executives
Geoffrey Race director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz director C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks officer: See Remarks C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster director, officer: PRESIDENT AND CEO C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire officer: CHIEF MEDICAL OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis officer: CHIEF SCIENTIFIC OFFICER C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein director 35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik director GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow officer: General Counsel and Secretary 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani officer: VP of Finance and Treasurer 35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson director C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon director, 10 percent owner 86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp 10 percent owner 399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116

F-star Therapeutics (F-star Therapeutics) Headlines

From GuruFocus

F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

By PurpleRose PurpleRose • 08-11-2022

F-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific Antibody

By PurpleRose PurpleRose • 07-20-2022

SHAREHOLDER ALERT: Weiss Law Investigates F-star Therapeutics, Inc.

By PRNewswire PRNewswire • 06-24-2022

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

By GuruFocusNews GuruFocusNews • 07-09-2022

F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

By GuruFocusNews GuruFocusNews • 06-29-2022

invoX Pharma and F-star Therapeutics issue Joint Statement

By Stock market mentor Stock market mentor • 01-26-2023

invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs

By GuruFocusNews GuruFocusNews • 07-03-2022

FSTX STOCK ALERT: Halper Sadeh LLP Is Investigating Whether the Sale of F-star Therapeutics, Inc. Is Fair to Shareholders

By Business Wire Business Wire • 07-14-2022

F-STAR THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of F-star Therapeutics, Inc. - FSTX

By Business Wire Business Wire • 07-16-2022

Investor Alert - The M&A Class Action Firm Announces an Investigation of F-star Therapeutics, Inc. - FSTX

By PRNewswire PRNewswire • 06-28-2022